Week in Review: Sinovac's Privatization Offer Draws $459 Million Outside Bid

Deals and Financings --Shandong Sinobioway offered $459 million to acquire Beijing vaccine maker Sinovac, a 14% premium to management's earlier privatization bid; --AGIC Capital of Hong Kong will acquire Ritedose Corporation, a US formulation/blow-fill-seal company, for approximately $700 million; --Guangzhou broke ground on a major new $800 million biopharma park partnered with General Electric; --CSPC Pharma of Hong Kong acquired global rights to two pre-clinical drug candidates from University of Texas institutions in a $114 million deal; --Vivace Therapeutics, a Bay-area oncology company, raised $40 million in two venture rounds from China-US investors; --Zai Lab, a Shanghai novel drug development/in-licensing company, closed a $30 million Series C round; --iCarbonX, a China big data/AI startup, participated in a $8.4 million series B funding of HealthLoop, a California company that facilitates patient-doctor contact;--India's Biological E. Limited in-licensed rights to two Takeda vaccines for India, China and low/middle income countries; Trials and Approvals --Hutchison China MediTech (Chi-Med) and AstraZeneca announced the start of a global Phase III trial of their partnered drug, the c-MET inhibitor savolitinib, for US-Europe approvals. More details.... Stock Symbols: (SZE: 002581) (NSDQ: SVA) (NYSE: GE) (HK: 1093) (TSE: 4502) (AIM/NSDQ: HCM) (NYSE: AZN) Share this with colleagues: // //